16 results on '"Katalinic, Alexander"'
Search Results
2. Temporal trends in age- and stage-specific incidence of colorectal adenocarcinomas in Germany
- Author
-
Waldmann, Annika, Borchers, Pia, and Katalinic, Alexander
- Published
- 2023
- Full Text
- View/download PDF
3. Krebsregister und Gesundheitswesen: Anfragen bei Verdacht auf Krebshäufungen, Erwartungen und Befürchtungen
- Author
-
Pritzkuleit, Ron, Katalinic, Alexander, and Gieseler, Frank
- Published
- 2017
- Full Text
- View/download PDF
4. How Can Data from German Cancer Registries Be Used for Research Purposes?
- Author
-
Katalinic, Alexander, Bock, H.-H., editor, Gaul, W., editor, Vichi, M., editor, Arabie, Ph., editor, Baier, D., editor, Critchley, F., editor, Decker, R., editor, Diday, E., editor, Greenacre, M., editor, Lauro, C., editor, Meulman, J., editor, Monari, P., editor, Nishisato, S., editor, Ohsumi, N., editor, Opitz, O., editor, Ritter, G., editor, Schader, M., editor, Weihs, C., editor, Baier, Daniel, editor, and Wernecke, Klaus-Dieter, editor
- Published
- 2005
- Full Text
- View/download PDF
5. Cancer survival in Eastern and Western Germany after the fall of the iron curtain
- Author
-
Jansen, Lina, Gondos, Adam, Eberle, Andrea, Emrich, Katharina, Holleczek, Bernd, Katalinic, Alexander, Brenner, Hermann, and GEKID Cancer Survival Working Group
- Published
- 2012
- Full Text
- View/download PDF
6. Divergent Patterns and Trends in Breast Cancer Incidence, Mortality and Survival Among Older Women in Germany and the United States
- Author
-
Jansen, Lina, Holleczek, Bernd, Kraywinkel, Klaus, Weberpals, Janick, Schröder, Chloé Charlotte, Eberle, Andrea, Emrich, Katharina, Kajüter, Hiltraud, Katalinic, Alexander, Kieschke, Joachim, Nennecke, Alice, Sirri, Eunice, Heil, Joerg, Schneeweiss, Andreas, Brenner, Hermann, and The GEKID Cancer Survival Working Group
- Subjects
trends ,Cancer Research ,United States ,Survival ,Trends ,Mortality ,Incidence ,Breast cancer ,Germany ,Breast cancer mortality ,Population ,survival ,lcsh:RC254-282 ,Article ,03 medical and health sciences ,breast cancer ,0302 clinical medicine ,Medicine ,030212 general & internal medicine ,Stage (cooking) ,Mortality trends ,education ,education.field_of_study ,Relative survival ,business.industry ,Incidence (epidemiology) ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,mortality ,Cancer registry ,Oncology ,030220 oncology & carcinogenesis ,incidence ,business ,Demography - Abstract
Background: Breast cancer treatment has changed tremendously over the last decades. In addition, the use of mammography screening for early detection has increased strongly. To evaluate the impact of these developments, long-term trends in incidence, mortality, stage distribution and survival were investigated for Germany and the United States (US). Methods: Using population-based cancer registry data, long-term incidence and mortality trends (1975&ndash, 2015), shifts in stage distributions (1998&ndash, 2015), and trends in five-year relative survival (1979&ndash, 2015) were estimated. Additionally, trends in five-year relative survival after standardization for stage were explored (2004&ndash, 2015). Results: Age-standardized breast cancer incidence rates were much higher in the US than in Germany in all periods, whereas age-standardized mortality began to lower in the US from the 1990s on. The largest and increasing differences were observed for patients aged 70+ years with a 19% lower incidence but 45% higher mortality in Germany in 2015. For this age group, large differences in stage distributions were observed, with 29% (Germany) compared to 15% (US) stage III and IV patients. Age-standardized five-year relative survival increased strongly between 1979&ndash, 1983 and 2013&ndash, 2015 in Germany (+17% units) and the US (+19% units) but was 9% units lower in German patients aged 70+ years in 2013&ndash, 2015. This difference was entirely explained by differences in stage distributions. Conclusions: Overall, our results are in line with a later uptake and less extensive utilization of mammography screening in Germany. Further studies and efforts are highly needed to further explore and overcome the increased breast cancer mortality among elderly women in Germany.
- Published
- 2020
7. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study.
- Author
-
Sant, Milena, Meneghini, Elisabetta, Bastos, Joana, Rossi, Paolo Giorgi, Guevara, Marcela, Innos, Kaire, Katalinic, Alexander, Majuelo, Leire Gil, Marcos-Gragera, Rafael, Molinié, Florence, Rapiti, Elisabetta, Vizcaino, Ana, Zadnik, Vesna, Minicozzi, Pamela, the European High Resolution Working Group on breast cancer, Van Eycken, L., Henau, K., Innos, K., Mägi, M., and Binder-Foucard, F.
- Abstract
Purpose: Endocrine therapy (ET) is the mainstream adjuvant treatment for ER-positive breast cancer (BC). We analysed 9293 ER-positive BC patients diagnosed in nine European countries in 2009–2013 to investigate how comorbidities at diagnosis, age, stage and subtype affected ET use over time, and relapse. Methods: Adjusted odds ratios (ORs) and 95% confidence intervals (95%CIs) of receiving ET were estimated according to Charlson comorbidity, age, stage and subtype using logistic regression. The 2-year cumulative incidence and adjusted sub-hazard ratios (SHRs) of relapse were estimated using competing risk analysis, with all-cause death as the competing event. The z-test was used to assess differences in the proportion of patients receiving ET in 1996–1998 and 2009–2013. Results: Ninety percent of the patients started adjuvant ET, range 96% (Belgium, Estonia, Slovenia, Spain)—75% (Switzerland). ORs of starting ET were lower for women aged > 75 years, with severe comorbidities, or luminal B HER2-positive cancer. The factors independently increasing the risk of relapse were: not receiving ET (SHR 2.26, 95%CI 1.02–5.03); severe comorbidity (SHR 1.94, 95%CI 1.06–3.55); luminal B, either HER2 negative (SHR 3.06, 95%CI 1.61–5.79) or positive (SHR 3.10, 95%CI 1.36–7.07); stage II (SHR 3.20, 95%CI 1.56–6.57) or stage III (SHR 7.41, 95%CI 3.48–15.73). ET use increased significantly but differently across countries from 51–85% in 1996–1998 to 86–96% in 2009–2013. Conclusions: ER-positive BC patients in Europe are increasingly prescribed ET but between-country disparities persist. Older women and women with severe comorbidity less frequently receive ET. ET omission and severe comorbidity independently predict early disease relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries.
- Author
-
Chen, Tianhui, Brenner, Hermann, Fallah, Mahdi, Jansen, Lina, Castro, Felipe A., Geiss, Karla, Holleczek, Bernd, Katalinic, Alexander, Luttmann, Sabine, Sundquist, Kristina, Ressing, Meike, Xu, Leiting, and Hemminki, Kari
- Abstract
Along with the increasing incidence and favorable prognosis, more women diagnosed with endometrial cancer may develop second primary cancers (SPCs). We aimed at investigating risk of SPCs after endometrial cancer in Germany and Sweden to provide insight into prevention strategies for SPCs. Endometrial cancer patients diagnosed at age ≥15 years in Germany during 1997-2011 and in Sweden nationwide during 1997-2012 were selected. Standardized incidence ratios (SIRs), calculated as the ratio of observed to expected numbers of cases, were used to assess the risk of a specific second cancer after endometrial cancer for both German and Swedish datasets. Among 46,929 endometrial cancer survivors in Germany and 18,646 in Sweden, overall 2,897 and 1,706 SPCs were recorded, respectively. Significantly elevated SIRs were observed in Germany for ovarian (SIR = 1.3; 95%CI:1.1-1.5) and kidney cancers [1.6 (1.3-1.8)], while in Sweden the SIRs were 5.4 (4.6-6.3) and1.4 (1.0-1.9), respectively. Elevated risk for second ovarian endometrioid carcinoma was pronounced after early (<55 years) onset endometrial cancer in Germany [9.0 (4.8-15)] and Sweden [7.7 (5.1-11)]. In Germany elevated risks were found for second ovarian endometrioid carcinoma after endometrioid histology of first endometrial cancer [6.3 (4.0-9.4)] and for second kidney cancer after clear cell histology of endometrial cancer [4.9 (1.6-11)]. We found exceptionally elevated risk of second ovarian endometrioid carcinoma after endometrial cancer of the same histology or of early onset. Risk for second kidney cancer was also increased, particularly after endometrial cancer of clear cell histology. Cancer prevention strategies should focus on these cancers after endometrial cancer diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
9. Krebsregister und Gesundheitswesen.
- Author
-
Pritzkuleit, Ron, Katalinic, Alexander, and Gieseler, Frank
- Abstract
Copyright of Der Onkologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2017
- Full Text
- View/download PDF
10. Survival of patients with gastric lymphoma in Germany and in the United States.
- Author
-
Castro, Felipe A, Jansen, Lina, Krilaviciute, Agne, Katalinic, Alexander, Pulte, Dianne, Sirri, Eunice, Ressing, Meike, Holleczek, Bernd, Luttmann, Sabine, and Brenner, Hermann
- Subjects
GASTRIC diseases ,LYMPHOMAS ,B cell lymphoma ,MUCOSA-associated lymphoid tissue lymphoma ,CANCER ,MEDICINE ,PATIENTS ,THERAPEUTICS - Abstract
Background and Aim This study aims to examine survival for gastric lymphomas and its main subtypes, mucosa-associated lymphoid tissue lymphoma ( MALT), and diffuse large B-cell lymphoma ( DLBCL), in Germany and in the United States. Methods Data for patients diagnosed in 1997-2010 were used from 10 population-based German cancer registries and compared to the data from the US Surveillance, Epidemiology and End Results ( SEER) 13 registries database. Patients age 15-74 diagnosed with gastric lymphomas were included in the analysis. Period analysis and modeled period analysis were used to estimate 5-year and 10-year relative survival ( RS) in 2002-2010 and survival trends from 2002-2004 to 2008-2010. Results Overall, the database included 1534 and 2688 patients diagnosed with gastric lymphoma in 1997-2010 in Germany and in the United States, respectively. Survival was substantially higher for MALT (5-year and 10-year RS: 89.0% and 80.9% in Germany, 93.8% and 86.8% in the United States) than for DLBCL (67.5% and 59.2% in Germany, and 65.3% and 54.7% in the United States) in 2002-2010. Survival was slightly higher among female patients and decreased by age for gastric lymphomas combined and its main subtypes. A slight, nonsignificant, increase in the 5-year RS for gastric lymphomas combined was observed in Germany and the United States, with increases in 5-year RS between 2002-2004 and 2008-2010 from 77.1% to 81.0% and from 77.3% to 82.0%, respectively. Five-year RS of MALT exceeded 90% in 2008-2010 in both countries. Conclusions Five-year RS of MALT meanwhile exceeds 90% in both Germany and the United States, but DLBCL has remained below 70% in both countries. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Recent cancer survival in Germany: An analysis of common and less common cancers.
- Author
-
Jansen, Lina, Castro, Felipe A., Gondos, Adam, Krilaviciute, Agne, Barnes, Benjamin, Eberle, Andrea, Emrich, Katharina, Hentschel, Stefan, Holleczek, Bernd, Katalinic, Alexander, and Brenner, Hermann
- Abstract
The monitoring of cancer survival by population-based cancer registries is a prerequisite to evaluate the current quality of cancer care. Our study provides 1-, 5- and 10-year relative survival as well as 5-year relative survival conditional on 1-year survival estimates and recent survival trends for Germany using data from 11 population-based cancer registries, covering around one-third of the German population. Period analysis was used to estimate relative survival for 24 common and 11 less common cancer sites for the period 2007-2010. The German and the United States survival estimates were compared using the Surveillance, Epidemiology and End Results 13 database. Trends in cancer survival in Germany between 2002-2004 and 2008-2010 were described. Five-year relative survival increased in Germany from 2002-2004 to 2008-2010 for most cancer sites. Among the 24 most common cancers, largest improvements were seen for multiple myeloma (8.0% units), non-Hodgkin lymphoma (6.2% units), prostate cancer (5.2% units) and colorectal cancer (4.6% units). In 2007-2010, the survival disadvantage in Germany compared to the United States was largest for cancers of the mouth/pharynx (−11.0% units), thyroid (−6.8% units) and prostate (−7.5% units). Although survival estimates were much lower for elderly patients in both countries, differences in age patterns were observed for some cancer sites. The reported improvements in cancer survival might reflect advances in the quality of cancer care on the population level as well as increased use of screening in Germany. The survival differences across countries and the survival disadvantage in the elderly require further investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998-2008.
- Author
-
Rusner, Carsten, Trabert, Britton, Katalinic, Alexander, Kieschke, Joachim, Emrich, Katharina, and Stang, Andreas
- Subjects
- *
GERMPLASM , *SPERMATOGENESIS , *EMBRYOLOGY , *OOGENESIS , *HEREDITY - Abstract
Background: Malignant gonadal (GGCT) and extragonal germ cell tumors [GCT (EGCT)] are thought to originate from primordial germ cells. In contrast to well reported population-based data of GGCTs in males, analyses of GGCTs in females and EGCTs in both sexes remain limited. Methods: In a pooling project of nine population-based cancer registries in Germany for the years 1998- 2008, 16,883 malignant GCTs and their topographical sites were identified using ICD-O morphology and topography for persons aged 15 years and older. We estimated age-specific and age-standardized incidence rates. Results: Among males, the incidence of testicular GCTs increased over time. In contrast, there was no increase in the incidence of EGCTs. Among females, rates of ovarian GCTs were stable, while rates of EGCTs declined over time. The most frequent extragonadal sites were mediastinum among males and placenta among females. Conclusions: Our results underline different incidence trends and distinct age-specific incidence patterns of malignant GGCTs and EGCTs, as reported recently by several population-based registries. The differences suggest that GGCT and EGCT may have different etiologies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Lung cancer survival in Germany: A population-based analysis of 132,612 lung cancer patients.
- Author
-
Eberle, Andrea, Jansen, Lina, Castro, Felipe, Krilaviciute, Agne, Luttmann, Sabine, Emrich, Katharina, Holleczek, Bernd, Nennecke, Alice, Katalinic, Alexander, and Brenner, Hermann
- Subjects
- *
LUNG cancer treatment , *CANCER-related mortality , *HISTOLOGY , *CANCER invasiveness , *MEDICAL registries - Abstract
Objectives Lung cancer is the most common cancer-related death worldwide. In Germany it accounts for 25% of cancer deaths in men, and 14% in women. The aim of this study is to provide an overview of 5-year relative survival by sex, age, histology, and tumour stage in Germany representing a population of 26.7 million people. Materials and methods The study is based on a pooled German dataset including data from 12 population-based cancer registries covering around one third of the German population. A total of 132,612 patients diagnosed with lung cancer from 2002 to 2010 were included in the analysis. Survival estimates for the time period 2007–2010 were calculated using period analysis. Differences in survival between sexes were tested for statistical significance by model-based period analysis (poisson regression model). The relative excess risk (RER) of death (women vs. men) was extracted from the model with the p value for the difference in RER. Results The overall age adjusted 5-year relative survival was 15.5% (standard error (SE) 0.2) for men and 20.3% (SE 0.3) in women. Survival differed markedly according to age (men: <60 years 18.5% vs. 80+ years 8.4% and women 23.7% vs. 10.6%, respectively), histology (largest difference between histological groups: men 25.7 and women 44.4% points) and stage (men: UICC Ia 62.9%, vs. UICC IV 4.6% and women 75.2% vs. 7.0%, respectively). Our study showed survival advantages for women compared to men, most notably in younger aged patients (RER 0.83, p < 0.0001), patients with adenocarcinoma (RER 0.80, p < 0.0001), and patients with lower stage cancer (RER 0.62, p < 0.0001). Conclusions This study presents up-to-date survival estimates for lung cancer in Germany. Compared to other European countries survival was relatively high. Women showed higher survival than men independent of age, histology and stage. The reasons for the survival differences require further clarification. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries.
- Author
-
Chen, Tianhui, Fallah, Mahdi, Jansen, Lina, Castro, Felipe A., Krilavicuite, Agne, Katalinic, Alexander, Eisemann, Nora, Emrich, Katharina, Holleczek, Bernd, Geiss, Karla, Eberle, Andrea, Sundquist, Jan, Brenner, Hermann, Hemminki, Kari, and GEKID Cancer Survival Working Group
- Abstract
We aimed at investigating the distribution and risk of all second discordant primary cancers (SDPCs) after a specific first primary cancer in Germany and Sweden to provide etiological understanding of SDPCs and insight into their incidence rates and recording practices. Among 1,537,004 survivors of first primary cancers in Germany and 588,103 in Sweden, overall 80,162 and 32,544 SDPCs were recorded, respectively. Standardized incidence ratios (SIRs) of all SDPCs were elevated at levels between 1.1 and 2.1 after 23 (out of overall 29) cancers in Germany and at levels between 1.1 and 1.6 after 24 cancers in Sweden, and among them, elevated SIRs were found after 19 cancers in both populations. Decreased SIRs at levels ranging from 0.5 to 0.9 were found for some cancers with poor prognosis in Germany only. We found elevated risk after 19 out of 29 cancers in both countries, suggesting common etiology of SDPCs after most of first cancers and registration similarity. Decreased risks after some fatal cancers were found only in Germany, which may be attributed to reporting practices or missed death data in Germany. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
15. Population-based hormone receptor-specific incidence trends of breast cancer in Germany
- Author
-
Rusner, Carsten, Bandemer-Greulich, Ulrike, Engel, Jutta, Stegmaier, Christa, Zawinell, Anette, Holleczek, Bernd, Katalinic, Alexander, Kuss, Oliver, Schmidt-Pokrzywniak, Andrea, Schubert-Fritschle, Gabriele, Tillack, Anett, and Stang, Andreas
- Subjects
- *
BREAST cancer , *HORMONE receptors , *POSTMENOPAUSE , *CONFIDENCE intervals , *HORMONE therapy , *WOMEN'S health - Abstract
Abstract: Objectives: Several countries reported a drop in prescription of hormone replacement therapy (HRT) in the 2000s, followed by decreases in breast cancer incidence among postmenopausal women aged 50–69 years. The aim of this study was to provide hormone receptor specific incidence rates of breast cancer in Germany. Methods: Breast cancer data were extracted from the cancer registries of the Federal States of Brandenburg and Saarland and the area of Munich for the period from 1998 to 2007. We obtained nationwide data on HRT prescription in 1998–2007 from health insurances. Multiple imputation was used on missing values for the receptor status. Age-standardized (European standard population) and age-specific rates were calculated. Results: The age-standardized incidence rates in breast cancer were virtually constant over the entire period in all regions. In particular, no substantial changes over time occurred within the age- and receptor-specific analyses. In the same period we observed a drop in HRT use, starting in 1999 and leveling off in 2004. The incidence trends of carcinoma in situ of the female breast increased during the study period. Conclusions: In our data, we did not observe an association between the decline in HRT prescription and breast cancer incidence among women aged from 50 to 69 years. The lack of temporal changes in breast cancer incidence may be explained by introduction of opportunistic and organized mammography screening and low absolute levels of HRT prescription in Germany. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. Impact of the Quality assured Mamma Diagnostic (QuaMaDi) programme on survival of breast cancer patients
- Author
-
Obi, Nadia, Waldmann, Annika, Schäfer, Fritz, Schreer, Ingrid, and Katalinic, Alexander
- Subjects
- *
QUALITY assurance , *BREAST cancer diagnosis , *HEALTH surveys , *EPIDEMIOLOGY , *CANCER-related mortality , *MAMMOGRAMS , *MEDICAL screening - Abstract
Abstract: Objective: To evaluate the effect of the Quality assured Mamma Diagnostic programme (QuaMaDi) introduced in 2001 on breast cancer and mortality on a population basis. QuaMaDi provides a standardized diagnostic process for symptomatic or at risk women of all ages. The process includes independent double-reading of mammograms, additional ultrasound, and if suspicious an expert reading and assessment. We tested the hypothesis that QuaMaDi has influenced breast cancer epidemiology and survival positively. Methods: The QuaMaDi cohort of breast cancer patients, diagnosed within the programme between 2001 and 2007, was linked to the cancer registry dataset of all breast cancer cases in Schleswig-Holstein, Germany. By this record-linkage procedure participants of QuaMaDi could be marked in the cancer registry data. Overall survival rates of 3096 patients diagnosed within QuaMaDi were compared to 5417 patients diagnosed outside QuaMaDi, matched by year of diagnosis, using multivariate Cox proportional hazard models. Results: Crude hazard ratio for overall survival was HR 0.43 (95% CI 0.35–0.52) for breast cancer cases detected inside QuaMaDi versus those diagnosed outside the programme. After stepwise adjustment for age, grading, histology, treatment, and tumour stage, the survival advantage in QuaMaDi diagnosed breast cancer patients was still statistically significant (HR 0.78, 95% CI 0.64–0.96). Conclusion: Evidence is provided that the QuaMaDi programme has a beneficial impact on the first 5-year overall survival rate after breast cancer beyond a favourable tumour stage distribution. Thus, we conclude that QuaMaDi contributes to improved health care for women, who are not eligible for mammography screening. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.